Virtual Library
Start Your Search
N. Sone
Author of
-
+
P2.01 - Advanced NSCLC (ID 618)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 10/17/2017, 09:00 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.01-001 - Serum Albumin Level Predicts the Survival Benefit of Chemotherapy in Elderly Advanced NSCLC Patients with Poor Performance Status (ID 7326)
09:00 - 09:00 | Author(s): N. Sone
- Abstract
Background:
There have been few data on the chemotherapy in elderly advanced non-small cell lung cancer (NSCLC) patients with poor performance status (PS), and usefulness of chemotherapy for such patients remains unclear.
Method:
All consecutive patients with advanced NSCLC, elerly (≥75 years old), ECOG PS ≥2, EGFR mutation negative/unknown, and newly diagnosed from January 2009 to December 2012 at Kurashiki Central Hospital, were retrospectively reviewed to clarify the factors which predicts the survival benefit of chemotherapy.
Result:
59 patients were enrolled. 31 patients received at least one chemotherapy regimen (chemotherapy group), whereas 28 patients received best supportive care (BSC) alone (BSC group). The proportion of PS 2 and serum albumin level were significantly higher in the chemotherapy group than in the BSC group. The overall survival (OS) was longer in the chemotherapy group than in the BSC group (median OS of 4.7 months and 3.1 months, p = 0.0119). In the chemotherapy group, log-rank testing did not show statistically significant differences in OS between single-agent therapy group and carboplatin-based doublet therapy group, whereas the OS of the patients who received chemotherapy for only 1 cycle was significantly better than those of the patients who received chemotherapy for ≥ 2 cycles. Hypoalbuminemia was not only the risk factor for the early termination of chemotherapy, but also the independent prognostic factor in the chemotherapy group. A receiver operating characteristic curve analysis showed that the best cut-off value was 3.40 g/dl. In the patients with serum albumin ≥ 3.40 g/dl, OS was significantly longer in chemotherapy group than that in BSC group (p=0.0156), whereas, the patients with serum albumin < 3.40 g/dl exhibited poor prognosis regardless of presence/absence of chemotherapy. Figure 1
Conclusion:
In the elderly advanced NSCLC patients with poor PS, serum albumin level may help identify the patients who are more likely to benefit from chemotherapy.
